The EU Commission sends SOs to two pharmaceutical companies over possible delayed entry of generic (Johnson & Johnson and Novartis)

On 31 January 2013, the European Commission announced that it had sent a Statement of Objections (“SO”) to pharmaceutical companies Johnson & Johnson (“J&J”) and Novartis over

Access to this article is restricted to subscribers

Already Subscribed? Sign-in

Access to this article is restricted to subscribers.

Read one article for free

Sign-up to read this article for free and discover our services.

 

PDF Version

Author

Quotation

Peter L'Ecluse, The EU Commission sends SOs to two pharmaceutical companies over possible delayed entry of generic (Johnson & Johnson and Novartis), 31 January 2013, e-Competitions Bulletin Competition in the Pharmaceutical sector, Art. N° 58203

Visites 109

All issues

  • Latest News issue 
  • All News issues
  • Latest Special issue 
  • All Special issues